Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Potassium loss in hyperaldosteronism: a new MRI insight

NCT ID NCT04251780

Knowledge-focused Sponsor: University of Erlangen-Nürnberg Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether potassium levels in body tissues change in people with primary hyperaldosteronism, a condition causing high blood pressure and electrolyte imbalances. Researchers used a special MRI technique to measure potassium in 21 patients before and after treatment. The goal was to understand how the body handles potassium in this condition, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

21 people

The number who actually took part.

Started

Jan 2018

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with Primary Aldosteronism Healthy participants

Ages

18 to 95 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients with Primary Aldosteronism: * Primary Aldosteronism diagnosed according to the endocrinological guideline (J Clin Endocrinology \& Metabolism, May 2016) without specific medication * Age \> 18 years Exclusion Criteria for patients with Primary Aldosteronism: * Chronic kidney disease ≤ 3b (estimated GFR \<45 ml/min according to CKD-EPI) * Active malignancy * Severe congestive heart failure (NYHA III and IV) * Liver cirrhosis (Child B and C) * Acute infection * Recent major surgical procedures (\<3 months) * Pregnancy * Contraindications for MRI measurements: cardiac pacemaker, claustrophobia, etc. Inclusion Criteria for healthy control participants: \- Age \> 18 years Exclusion Criteria for healthy control participants: * Medical history of chronic disease (such as diabetes, hypertension, chronic kidney disease etc.) * regular medication * blood pressure ≥ 140/90 mmHg * Pregnancy * Contraindications for MRI measurements: cardiac Pacemaker, claustrophobia, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Electrolyte disturbance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Electrolyte disturbance Primary hyperaldosteronism

Contacts and locations

Locations

  • Nephrology Department, University Hospital Erlangen

    Erlangen, Bavaria, 91054, Germany

  • Radiology Department, University Hospital Erlangen

    Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.